Stenocare Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Thomas Schnegelsberg

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	7.1yrs
Participación del CEO	n/a
Permanencia media de la dirección	7.1yrs
Promedio de permanencia en la Junta Directiva	6.2yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Thomas Schnegelsberg (59 yo)

7.1yrs

Permanencia

Mr. Thomas Skovlund Schnegelsberg serves as Chief Executive Officer since October 2017 and Co-Founder of Stenocare A/S. Mr. Schnegelsberg serves as Deputy Chairman of Bagsværd Kost- & Gymnasium Skole. Mr....

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Thomas Schnegelsberg	CEO, Co-Founder & Member of Executive Board	7.1yrs	sin datos	sin datos
Rolf Petersen	Co-Founder & Chief Commercial Officer	no data	sin datos	8.37% € 502.1k
Soren Kjaer	Co-Founder & COO	7.8yrs	sin datos	sin datos
Peter Johansen	Chief Financial Officer	6.3yrs	sin datos	sin datos

7.1yrs

Permanencia media

59.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de S7C es experimentado (7.1 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Jeppe Petersen	Independent Director	6.2yrs	sin datos	sin datos
Marianne Wier	Non Executive Independent Chairman	6.2yrs	sin datos	sin datos
Soren Frederiksen	Independent Director	6.2yrs	sin datos	sin datos

6.2yrs

Permanencia media

58yo

Promedio de edad

Junta con experiencia: La junta directiva de S7C se considera experimentada (6.2 años de antigüedad promedio).

Stenocare Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Insufficient new directors

Stenocare A/S Announces Resignation of Søren Kjær as Board Member

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Insufficient new directors

Third quarter 2024 earnings released

Stenocare A/S to Report Q1, 2025 Results on May 08, 2025

Stenocare A/S Announces Resignation of Søren Kjær as Board Member

Stenocare A/S Updates Earnings Guidance for the Year 2024

Second quarter 2024 earnings released

New major risk - Market cap size

Stenocare A/S Updates Sales Guidance for the Year 2024

Stenocare A/S Launches Next Generation Medical Cannabis Oil Product in Australia

First quarter 2024 earnings released

Stenocare A/S to Report Fiscal Year 2024 Results on Feb 27, 2025

Stenocare A/S Announces That the New STENOCARETHC/CBD Medical Cannabis Oil Product Available for Sale in Denmark

Stenocare A/S to Deliver New Medical Cannabis Oil Product for Australian Patients

STENOCARE Receives Approval to Sell a New Medical Cannabis Oil Product in Denmark

Full year 2023 earnings released: kr.1.18 loss per share (vs kr.1.40 loss in FY 2022)

Stenocare A/S to Report Q1, 2024 Results on May 02, 2024

New major risk - Shareholder dilution

Stenocare A/S Expands Presence with New Medical Cannabis Oil Product

Less than half of directors are independent

Stenocare Ready to Ship Medical Cannabis to German Patients

Stenocare A/S Provides Sales Guidance for the Year 2023

Stenocare A/S Provides Update on Their Strong Danish Product Pipeline

First quarter 2023 earnings released

New minor risk - Shareholder dilution

Stenocare A/S Reports on Significant Progress in Development of Its New Innovative Medical Cannabis Product

Stenocare A/S Launches IT-Platform for Online Clinics

Full year 2022 earnings released

Less than half of directors are independent

Stenocare A/S Provides Sales Guidance for the Year 2023

Stenocare's New STENOCARE CBD Medical Cannabis Oil Product Is Available in Denmark

Less than half of directors are independent

Stenocare A/S Reaffirms Sales Guidance for the Fourth Quarter of 2022 and Provides Sales Guidance for the Year 2023

Third quarter 2022 earnings released

Stenocare A/S Receives Approval from the Danish Medicines Agency to Sell New Cbd Medical Cannabis Oil Product to Danish Patients

Stenocare A/S Announces Results from New Medical Cannabis Oil Study

Second quarter 2022 earnings released

First quarter 2022 earnings released

Less than half of directors are independent

Stenocare A/S and Solural Pharma Announce Positive Outcome of Feasibility Study

Stenocare A/S Approves to Supply Danish Patients with Medical Cannabis Oil Products

First quarter 2021 earnings released

More Choice for Treatment of Swedish Patients with Medical Cannabis Oil

Emerald Health Therapeutics, Inc. Announces That Its Partner, Stenocare A/S, Completed Its First Shipment and Delivery of Emerald Medical Cannabis Oil

New 90-day high: €2.42

STENOCARE A/S and Emerald Health Therapeutics Inc Announces First Shipment and Delivery of Medical Cannabis Oil

New 90-day high: €2.41

Stenocare A/S to Report Q1, 2021 Results on May 06, 2021

Stenocare A/S to Report Q2, 2021 Results on Aug 19, 2021

New 90-day low: €1.99

Stenocare A/S (Denmark) to Be from Other OTC

Stenocare A/S to Report Fiscal Year 2020 Results on Feb 25, 2021

Earnings released

Stenocare A/S to Report Q3, 2020 Results on Nov 05, 2020

CEO

Permanencia

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad